At the Aesthetics Conference & Exhibition (ACE) 2022 on March 11-12, Galderma will be unveiling Restylane EYELIGHT.
By targeting the tear trough and using the original NASHA technology, Restylane EYELIGHT lets you offer patients a treatment with predictable results to tackle under-eye shadows.1-3 What patients and their friends should see is a less tired and more refreshed look,1-3 whilst still looking natural.1,2
Come and find out more at the two Galderma symposiums being held at ACE on both days, with LIVE demonstrations from Dr Kuldeep Minocha and Dr Munir Somji:
- An introduction to Restylane EYELIGHT: Mastering tear trough treatments with Galderma
- Bright Eyes by Galderma: Bring brightness back with an individual treatment plan for a fresh look.
References:
- Verpaele A, Strand A, Restylane SubQ, a non-animal stabilized hyaluronic acid gel for soft tissue augmentation of the mid- and lower face. Aesthetic Surgery Journal. 2006 Jan:26(1):S10-7.
- Nikolis A., Berros P., Enright KM., Cordoba M and Nguyen Q., A Randomized Crossover-controlled Evaluator-blinded Trial Evaluating Cannula- Vs Needle-assisted Hyaluronic Acid Injections for Infraorbital Deformities. Aesthet Surg J sjab284 (2021).
- Data on file (MA-49047).
Adverse events should be reported. For the UK, Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for Yellow Card in the Google Play or Apple App Store. For Ireland, suspected adverse events can be reported via HPRA Pharmacovigilance, Website: www.hpra.ie; Adverse events should also be reported to Galderma (UK) Ltd, Email: [email protected] Tel: +44 (0) 300 3035674.
